Biomarkers related to immunosenescence: relationships with therapy and survival in lung cancer patients
Conclusions
Distribution of lymphocyte subsets was influenced by cancer and chemotherapy in NSCLC patients. CD19 + B cells decrease by cancer disease and not by chemotherapy, and CD28− subpopulations increase by chemotherapy and not by cancer. The proportion of CD8 + CD28− T cells, CD4+ T cells and CD4/CD8 ratio can be used as predictive biomarkers of CIMAvax-EGF efficacy in NSCLC patients and thereby could, be a useful tool for a personalized treatment.
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
More News: Allergy & Immunology | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study | Vaccines